Skip to content


Tepezza (teprotumumab) is an antibody pharmaceutical. Teprotumumab was first approved as Tepezza on 2020-01-21. It is used to treat graves ophthalmopathy in the USA. The pharmaceutical is active against insulin-like growth factor 1 receptor.
Trade Name Tepezza
Common Name Teprotumumab
Indication graves ophthalmopathy
Drug Class Monoclonal antibodies
Get full access now